Evidence map›Paper›PMID 23360980›Full record

ArticleBiochimica et biophysica acta2013

MEK-1 activates C-Raf through a Ras-independent mechanism.

Deborah T Leicht, Vitaly Balan, Jun Zhu, Alexander Kaplun, Agnieszka Bronisz, Ajay Rana, Guri Tzivion

Abstract read
In one paragraph

Article in Biochimica et biophysica acta, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Drug resistance in targeted cancer therapies with RAF inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Deborah T LeichtDepartment of Pathology, Wayne State University, Detroit, MI 48201, USA.
Vitaly Balan
Jun Zhu
Alexander Kaplun
Agnieszka Bronisz
Ajay Rana
Guri Tzivion
Texas A&M University System · USWayne State University · US

Funding

TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
Role of Mixed Lineage Kinase 3/SPRK in Stress SignalingR01GM055835 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI RANA, AJAY NMN · 1999 to 2010
$1.8M
Oncogenic MLK3-Pak1 Signaling in ER Negative Breast CancerR01CA176846 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, AJAY NMN · 2013 to 2017
$1.6M
Regulation of c-Raf-1 by Ras and Growth FactorsR01GM067134 · NIGMS · WAYNE STATE UNIVERSITY · PI TZIVION, GURI · 2003 to 2007
$1.3M
NCI NIH HHS R01 CA176846NCI NIH HHS T32 CA009531NCI NIH HHS T32-CA09531-19NIGMS NIH HHS GM055835NIGMS NIH HHS R01 GM055835NIGMS NIH HHS R01 GM067134
6 · The paper itself

Abstract

C-Raf is a member of the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) signaling pathway that plays key roles in diverse physiological processes and is upregulated in many human cancers. C-Raf activation involves binding to Ras, increased phosphorylation and interactions with co-factors. Here, we describe a Ras-independent in vivo pathway for C-Raf activation by its downstream target MEK. Using (32)P-metabolic labeling and 2D-phosphopeptide mapping experiments, we show that MEK increases C-Raf phosphorylation by up-to 10-fold. This increase was associated with C-Raf kinase activation, matching the activity seen with growth factor stimulation. Consequently, coexpression of wildtype C-Raf and MEK was sufficient for full and constitutive activation of ERK. Notably, the ability of MEK to activate C-Raf was completely Ras independent, since mutants impaired in Ras binding that are irresponsive to growth factors or Ras were fully activated by MEK. The ability of MEK to activate C-Raf was only partially dependent on MEK kinase activity but required MEK binding to C-Raf, suggesting that the binding results in a conformational change that increases C-Raf susceptibility to phosphorylation and activation or in the stabilization of the phosphorylated-active form. These findings propose a novel Ras-independent mechanism for activating the C-Raf and the MAPK pathway without the need for mutations in the pathway. This mechanism could be of significance in pathological conditions or cancers overexpressing C-Raf and MEK or in conditions where C-Raf-MEK interaction is enhanced due to the down-regulation of RKIP and MST2.

Indexed as

Mitogen-Activated Protein Kinase KinasesAnimalsCell DivisionChlorocebus aethiopsCOS CellsDown-RegulationHumansMAP Kinase Kinase 1MAP Kinase Signaling SystemMitogen-Activated Protein Kinase 3MutationPhosphorylationProtein Structure, TertiaryProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)MAP2K1 protein, humanMAP Kinase Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID23360980
PMCPMC3608709
OpenAlexW2047793293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.